{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:14:50Z","timestamp":1782414890800,"version":"3.54.5"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan","award":["17K18244"],"award-info":[{"award-number":["17K18244"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Fibroblast growth factor (FGF) 21 is an important regulator of glycemic control, but the association between circulating FGF21 and diabetic complications is poorly understood. Moreover, basal FGF21 secretion, especially in response to insulin dose, in patients with type 1 diabetes mellitus (T1DM), has not been well examined. Therefore, this study aimed to determine the association of circulating FGF21 levels with diabetic complications and insulin dosage in middle-aged and elderly patients with T1DM.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>A total of 127 middle-aged and elderly patients with T1DM, including 68 patients with diabetic complications, and 106 non-diabetic individuals were analyzed in this cross-sectional study. Information on demographic characteristics and T1DM was extracted from their electronic medical records. Serum FGF21 levels were determined using ELISA.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Serum FGF21 levels were significantly lower in T1DM patients (75.2 [37.4\u2013135.1] pg\/mL) than in non-diabetic participants (151.6 [92.0\u2013224.6] pg\/mL; P &lt; 0.001). No diabetic complications were associated with serum FGF21 concentrations. Both basal and bolus insulin doses were significantly and positively correlated with serum FGF21 levels (P &lt; 0.05). Stepwise multiple regression analysis showed that FGF21 level was associated with age and body mass index (P &lt; 0.05), while the basal insulin dose was an independent positive predictor of serum FGF21 levels (\u03b2 = 0.197, P = 0.032).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Circulating FGF21 levels are reduced in patients with T1DM; however, they are not associated with diabetic complications. In addition, aging, obesity, and insulin dosage are positive determinants of circulating FGF21.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0263774","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:26:28Z","timestamp":1645554388000},"page":"e0263774","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-8456","authenticated-orcid":true,"given":"Hirokazu","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Nirengi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"issue":"5","key":"pone.0263774.ref001","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast Growth Factor 21-Metabolic Role in Mice and Men","volume":"38","author":"H Staiger","year":"2017","journal-title":"Endocr Rev"},{"issue":"6","key":"pone.0263774.ref002","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"A Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"issue":"3","key":"pone.0263774.ref003","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/dmrr.1177","article-title":"Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity","volume":"27","author":"FL Mashili","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"pone.0263774.ref004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jdiacomp.2014.10.001","article-title":"Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes","volume":"29","author":"P Xu","year":"2015","journal-title":"J Diabetes Complications"},{"issue":"3","key":"pone.0263774.ref005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"G Gaich","year":"2013","journal-title":"Cell Metab"},{"issue":"2","key":"pone.0263774.ref006","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2016.12.004","article-title":"FGF21 Is an Exocrine Pancreas Secretagogue","volume":"25","author":"KC Coate","year":"2017","journal-title":"Cell Metab"},{"issue":"9","key":"pone.0263774.ref007","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.7150\/ijbs.25026","article-title":"The role of FGF21 in type 1 diabetes and its complications","volume":"14","author":"J Zhang","year":"2018","journal-title":"Int J Biol Sci"},{"issue":"1","key":"pone.0263774.ref008","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1210\/jc.2011-1930","article-title":"Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes","volume":"97","author":"Y Xiao","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"pone.0263774.ref009","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12020-014-0413-9","article-title":"Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls","volume":"48","author":"K Zibar","year":"2015","journal-title":"Endocrine"},{"issue":"3","key":"pone.0263774.ref010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12020-019-02027-3","article-title":"FGF21 and glycemic control in patients with T1D","volume":"65","author":"S Rosell Rask","year":"2019","journal-title":"Endocrine"},{"issue":"7","key":"pone.0263774.ref011","doi-asserted-by":"crossref","first-page":"E1224","DOI":"10.1210\/jc.2012-1132","article-title":"Dynamic change of serum FGF21 levels in response to glucose challenge in human","volume":"97","author":"Z Lin","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"pone.0263774.ref012","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1210\/jc.2017-01257","article-title":"FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans","volume":"102","author":"RJ Samms","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"pone.0263774.ref013","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40272-014-0064-6","article-title":"Insulin therapy in children and adolescents with type 1 diabetes","volume":"16","author":"FS Malik","year":"2014","journal-title":"Paediatr Drugs"},{"issue":"5","key":"pone.0263774.ref014","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"X Zhang","year":"2008","journal-title":"Diabetes"},{"issue":"9","key":"pone.0263774.ref015","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2337\/dc11-0294","article-title":"High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects","volume":"34","author":"C Chen","year":"2011","journal-title":"Diabetes Care"},{"issue":"10","key":"pone.0263774.ref016","doi-asserted-by":"crossref","first-page":"E1877","DOI":"10.1210\/jc.2014-1877","article-title":"Cardiorespiratory fitness and visceral fat are key determinants of serum fibroblast growth factor 21 concentration in Japanese men","volume":"99","author":"H Taniguchi","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"pone.0263774.ref017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","article-title":"Report of the committee on the classification and diagnostic criteria of diabetes mellitus","volume":"1","author":"Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes M","year":"2010","journal-title":"J Diabetes Investig"},{"key":"pone.0263774.ref018","unstructured":"Treatment guide for diabetes 2016\u20132017 edited by Japan diabetes society. Available from: http:\/\/www.jds.or.jp\/modules\/en\/index.php?content_id=1."},{"issue":"6","key":"pone.0263774.ref019","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"S Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"pone.0263774.ref020","first-page":"77","article-title":"Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals","volume":"2","author":"LJ Hanks","year":"2015","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"pone.0263774.ref021","doi-asserted-by":"crossref","first-page":"H1029","DOI":"10.1152\/ajpheart.00527.2015","article-title":"Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21","volume":"309","author":"EM Domouzoglou","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"27","key":"pone.0263774.ref022","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1016\/j.febslet.2008.10.021","article-title":"FGF21 is an Akt-regulated myokine","volume":"582","author":"Y Izumiya","year":"2008","journal-title":"FEBS Lett"},{"issue":"7\u20138","key":"pone.0263774.ref023","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2119\/molmed.2011.00075","article-title":"Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21","volume":"17","author":"DV Chartoumpekis","year":"2011","journal-title":"Mol Med"},{"issue":"11","key":"pone.0263774.ref024","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"FM Fisher","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"pone.0263774.ref025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2337\/dc12-0703","article-title":"Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians","volume":"36","author":"T Bobbert","year":"2013","journal-title":"Diabetes Care"},{"key":"pone.0263774.ref026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpeds.2016.11.029","article-title":"Lower Basal Insulin Dose is Associated with Better Control in Type 1","volume":"182","author":"D Strich","year":"2017","journal-title":"Diabetes. J Pediatr"},{"issue":"23","key":"pone.0263774.ref027","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235827","article-title":"Metabolically Active Brown Adipose Tissue Is Found in Adult Subjects with Type 1 Diabetes","volume":"20","author":"O Eriksson","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"pone.0263774.ref028","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cen.13162","article-title":"Acute endurance exercise lowers serum fibroblast growth factor 21 levels in Japanese men","volume":"85","author":"H Taniguchi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"pone.0263774.ref029","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1210\/jc.2015-3308","article-title":"Endurance Exercise Reduces Hepatic Fat Content and Serum Fibroblast Growth Factor 21 Levels in Elderly Men","volume":"101","author":"H Taniguchi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"pone.0263774.ref030","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"J Dushay","year":"2010","journal-title":"Gastroenterology"},{"issue":"7","key":"pone.0263774.ref031","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-136-7-200204020-00006","article-title":"Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials","volume":"136","author":"SP Whelton","year":"2002","journal-title":"Ann Intern Med"},{"issue":"9","key":"pone.0263774.ref032","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1172\/JCI74915","article-title":"FGF21 is an endocrine signal of protein restriction","volume":"124","author":"T Laeger","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"pone.0263774.ref033","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2014.09.008","article-title":"Fructose ingestion acutely stimulates circulating FGF21 levels in humans","volume":"4","author":"JR Dushay","year":"2015","journal-title":"Mol Metab"},{"key":"pone.0263774.ref034","doi-asserted-by":"crossref","first-page":"28183","DOI":"10.1038\/srep28183","article-title":"Single ingestion of soy beta-conglycinin induces increased postprandial circulating FGF21 levels exerting beneficial health effects","volume":"6","author":"T Hashidume","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0263774.ref035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3177\/jnsv.65.515","article-title":"Hepatic Fat Content Is Associated with Fasting-Induced Fibroblast Growth Factor 21 Secretion in Mice Fed Soy Proteins","volume":"65","author":"H Taniguchi","year":"2019","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"issue":"5","key":"pone.0263774.ref036","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1373\/clinchem.2010.155184","article-title":"Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans","volume":"57","author":"H Yu","year":"2011","journal-title":"Clin Chem"},{"issue":"2","key":"pone.0263774.ref037","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cmet.2008.06.014","article-title":"The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man","volume":"8","author":"C Galman","year":"2008","journal-title":"Cell Metab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0263774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:27:21Z","timestamp":1645554441000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0263774"}},"subtitle":[],"editor":[{"given":"Tomislav","family":"Bulum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0263774","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}